Archives: Speakers

Seoyeon Hyun

Seoyeon Hyun is the Head of Clinical Development at ILIAS Biologics. In her role, she is responsible for overseeing the overall clinical development of the company’s pipeline and leading global clinical trials for engineered exosome therapeutics.

With over 20 years of experience, she has handled various clinical development tasks, including Phase 1-3 clinical trials for new drug approvals as well as global clinical trials sponsored by multinational pharmaceutical companies. Before joining ILIAS Biologics in September 2021, she held a position overseeing new drug clinical development at a European biotech company, where she led multinational clinical trials in Europe. She has also served as a Clinical Research Manager at MSD and as a clinical project manager for new drug development at Boehringer Ingelheim and SK Chemicals.

Seoyeon Hyun holds a bachelor’s degree from Ewha Womans University College of Pharmacy and a master’s degree in physical pharmacy from Seoul National University.

Jessica Thongcharen

A highly skilled pharmacovigilance professional with vast experience in pharmacovigilance operations and regulatory intelligence in the APAC region and internationally. Strong leadership skills in both; project and people management with 18 years of working experience in the healthcare and pharmaceutical industry. Proven ability to set up new Pharmacovigilance (PV) operations, oversee PV compliance, audit, and quality management in the Asia Pacific region with positive track record of successful global PV audit and inspections. A qualified healthcare professional with post-graduate degrees in; Pharmacovigilance and Pharmacoepidemiology (specialized in Risk Identification and Quantification) and Business Administration.

Strong knowledge of relevant Codes of Conduct, aggregate reporting, compliance monitoring, safety databases and hands-on experiences in managing organization M&A as change agents.

Taegyun Park

2022 Sungkyunkwan University School of Medicine, Ph.D. Clinical Epidemiology

2019 Master of Pharmacy, Sungkyunkwan University Graduate School

1996 Bachelor of Pharmacy, Sungkyunkwan University Graduate School

2023 ~                Head of Research and development in Quratis

2016 ~ 2022(former) Medical Manager in ChungKundang

2001 ~ 2016(former) GSK Medical

Jaehyun Park

August, 2018 ~ Adjunct Professor, College of Pharmacy, Sunchon National University

January, 2023 ~ Managing Director, AniMusCure Inc., Suwon, Korea

< EDUCATION >

B.S. Pharmacy, College of Pharmacy, Sungkyunkwan University, Korea

M.S. Biochemistry, College of Pharmacy, Sungkyunkwan University, Korea

Ph.D. Biochemistry, College of Pharmacy, Sungkyunkwan University, Korea

< PROFESSIONAL EXPERIENCES >

– Assistant Manager, Kolon Pharmaceuticals Inc.

– Assistant Manager, Kolon Life Science, Ins., Seoul, Korea

– Research Fellow, Daewoong Pharmaceutical Co.

– Deputy Director, DanDi Bioscience, Inc.,

– Director, Selecxine, Inc.

– Managing Director, Genencell Co., Ltd.

Young Su (Bobby) Noh

Young Su (Bobby) Noh, Ph.D., is the Director, Clinical Research and Development (Oncology), Hanmi Pharma and a representative of IFPMA, ICH E22 informal Expert Working Group. Dr. Noh is also working as a committee member of KIC2025, an external Instructor in KoNECT and a reviewer of external evaluation committee of KDDF. Dr. Noh has been responsible for leading clinical program with NMEs or NBEs in multi-therapeutic area: including metabolic diseases and rare diseases as well as oncology and hematology for 17 years. Dr. Noh has a lot of experience for collaborating with global big pharma as well as biotech companies.

Previously, Dr. Noh served as an adjunct professor, department of regulatory science for Kyung Hee university and an expert, several guidelines Working Group of MFDS. Dr. Noh received his Ph.D. in pharmacy Kyung Hee University.

Tina Sun

With over 20 years of experience in clinical operations, Tina held leadership positions at Eli Lilly and Novartis, managing operations in Taiwan and Hong Kong. Besides her corporate roles, she led Transcelerate Taiwan since 2013 and served twice as the president of the Taiwan Clinical Research Association. Tina is interested in external engagement activities through her journey in clinical operations. Her authority in the field is demonstrated further through speaker roles at universities, conferences and clinical trial training programs, particularly on GCP-related topics.

Specialties

Global clinical trials operations and management

Speaker of clinical trial topics in GCP training program, university and conference

Professional Experiences

Trial Monitoring Country Head, Novartis (Taiwan)

Head of Clinical Operations, Eli Lilly and Company (Taiwan & Hong Kong)

President of Taiwan Clinical Research Association (5th ,TCRA)

Medical representative, clinical research associate, Novartis (Taiwan)

Pharmacist, Po-Ai Hospital

Sol Han

Sol Han currently serves as the Chief Medical Officer (CMO) and Head of Clinical Development at Cyrus Therapeutics, a company specializing in oncology drug development. In this pivotal role, Sol is spearheading critical phases of drug development, including Investigational New Drug (IND) application submissions, early-stage clinical development, and the successful translational research that bridges non-clinical findings to human clinical trials.
With a professional background in pharmacy at Ewha Woman’s University, Sol brings two decades of deep industry experience, including 15 years garnered at Global Big Pharma companies such as Roche, GSK, and Sanofi. During this tenure, Sol established a distinguished clinical professional career as a Global Leader, successfully pioneering clinical operations and development not only locally but also globally.
Leveraging this profound expertise gained within the patient-centric and trend-setting global pharmaceutical landscape, Sol is now at Cyrus Therapeutics, successfully integrating advanced clinical development know-how into the domestic biotech sector and proactively elevating the company’s clinical capabilities to a global standard.